Literature DB >> 18996912

The risks of celiac artery coverage during endoluminal repair of thoracic and thoracoabdominal aortic aneurysms.

Luis R Leon1, Joseph L Mills, William Jordan, Mark M Morasch, Margaret Kovacs, Gary J Becker, Bulent Arslan.   

Abstract

The risks of purposeful celiac artery coverage during endovascular thoracic aortic aneurysm repair (TEVAR) to obtain an adequate distal landing zone have received scant scientific attention. Patients undergoing TEVAR at 6 tertiary centers from January 2000 to June 2007 were identified (n = 434); cases requiring celiac artery exclusion (n = 19; 4.4% of the total) were analyzed. The mean follow-up was 8.7 months (range, 0.2-21.2). The mean patients' age was 73.6 years (range, 56-86); 57.9% were men. The mean aneurysm diameter was 6.7 cm (range, 5-8.6). In 2 patients, the celiac artery balloon occlusion test was performed prior to TEVAR. In both, intact collateral foregut circulation was seen. Both underwent TEVAR without celiac artery revascularization; 1 did well, whereas the other developed foregut ischemia. In 16 cases (84.2%), the celiac artery was not revascularized prior to TEVAR. In those patients, 19 complications were reported (3 deaths; 2 paraplegia). No similar events occurred in those who underwent celiac artery revascularization (n = 3). Celiac artery coverage during TEVAR is required in 4.4% of cases. TEVAR correlated with a nonnegligible number of major complications. Complications were more frequent and severe in patients who did not have celiac artery revascularization prior to TEVAR. Specific celiac artery coverage complications are rare and not readily predictable based on preprocedure arteriography.

Entities:  

Mesh:

Year:  2008        PMID: 18996912     DOI: 10.1177/1538574408322655

Source DB:  PubMed          Journal:  Vasc Endovascular Surg        ISSN: 1538-5744            Impact factor:   1.089


  8 in total

1.  Mycotic thoracoabdominal aneurysms.

Authors:  Usman Jaffer; Richard Gibbs
Journal:  Ann Cardiothorac Surg       Date:  2012-09

2.  Occlusion of the Celiac Artery during Endovascular Thoracoabdominal Aortic Aneurysm Repair Is associated with Increased Perioperative Morbidity and Mortality.

Authors:  Ryan W King; Ryan Gedney; Jean Marie Ruddy; Elizabeth A Genovese; Thomas E Brothers; Ravi K Veeraswamy; Mathew D Wooster
Journal:  Ann Vasc Surg       Date:  2020-02-05       Impact factor: 1.466

3.  Balloon-assisted coil embolization of the celiac trunk before endovascular aortic repair of thoracoabdominal aortic aneurysm.

Authors:  Masayuki Endo; Toshio Kaminou; Yasufumi Ohuchi; Kimihiko Sugiura; Shinsaku Yata; Akira Adachi; Tsuyoshi Kawai; Syohei Takasugi; Shuichi Yamamoto; Kensuke Matsumoto; Masayuki Hashimoto; Takashi Ihaya; Toshihide Ogawa
Journal:  Jpn J Radiol       Date:  2013-01-12       Impact factor: 2.374

4.  Weight loss caused by visceral artery disease.

Authors:  William L Clifton; Abby Kneitz; William E Cohn; Reynolds M Delgado
Journal:  Tex Heart Inst J       Date:  2013

5.  Acute pancreatitis caused by pancreatic ischemia after TEVAR combined with intentional celiac artery coverage and embolization of the branches of the celiac artery.

Authors:  Yohei Kawatani; Hirotsugu Kurobe; Yoshitsugu Nakamura; Yuji Suda; Yoshinori Okuma; Shinichiro Sato; Toru Hashimoto; Takaki Hori
Journal:  J Surg Case Rep       Date:  2017-02-23

6.  Celiac artery aneurysm diagnosis and repair in the postpartum female.

Authors:  Obteene Azimi-Ghomi; Kamran Khan; Kristian Ulloa
Journal:  J Surg Case Rep       Date:  2017-02-15

7.  Preoperative Diagnostic Angiogram and Endovascular Aortic Stent Placement for Appleby Resection Candidates: A Novel Surgical Technique in the Management of Locally Advanced Pancreatic Cancer.

Authors:  N Trabulsi; J S Pelletier; C Abraham; T Vanounou
Journal:  HPB Surg       Date:  2015-09-28

8.  Endovascular stent graft repair of aortogastric fistula caused by peptic ulcer after esophagectomy: A case report.

Authors:  Xiao-Qing Wei; Lei Song; Xue-Song Zhang; Kui-Yang Wang; Jie Wu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.